Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3BP-6121
- Development stage
- Preclinical
- Lead developer
- 3B Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
3BP-6121 is a preclinical-stage, small molecule radiopharmaceutical targeting P-cadherin (cadherin-3 or CDH3), which is highly expressed in various solid tumors, including breast, ovarian, and colorectal cancers. Developed by 3B Pharmaceuticals, the program utilizes a theranostic approach, with [68Ga]3BP-6121 serving as a PET imaging agent and [177Lu]3BP-6121 as a therapeutic radioligand to deliver targeted beta radiation to P-cadherin-expressing tumor cells.
- Other names
- [177Lu]3BP-6121[68Ga]3BP-6121
02
Targets
CDH3 (Cadherin-3)
Beyond the preview
Go deeper on 3BP-6121.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3BP-6121.